Test Price
2,800 AED✅ Home Collection Available
AMPD1 Gene Myopathy (Myoadenylate Deaminase Deficiency) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
UAE’s ISO 9001:2015 Certified NGS Test for AMPD1 Deficiency – 99.9% Diagnostic Sensitivity
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Interpretation by DHA-Licensed Specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (reply within 30 minutes).
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) test comprehensively screens the AMPD1 gene for pathogenic variants linked to myoadenylate deaminase deficiency, a metabolic myopathy causing exercise intolerance, myalgia, and heightened rhabdomyolysis risk. Suitable for diagnostic confirmation and family screening.
| Feature | Our Test (NGS) | Muscle Biopsy Enzymatic Assay |
|---|---|---|
| Diagnostic Precision | Single‑nucleotide resolution, full gene coverage | Indirect enzyme activity estimation; may miss heterozygous carriers |
| Methodology | Next-Generation Sequencing (Illumina NovaSeq) | Histochemical staining, AMP deaminase activity spectrophotometry |
| Turnaround Time | 3 – 4 Weeks | 4 – 8 Weeks (requires fresh frozen muscle) |
| Invasiveness | Peripheral blood draw or Dried Blood Spot | Open biopsy with local anaesthesia |
Physician Insight & Safety Protocols
“A positive AMPD1 result represents one component of the diagnostic pathway; it requires correlation with detailed phenotyping, family history, and functional assessments. Patients should avoid self‑interpreting variants of uncertain significance and must consult a specialist prior to altering any training or dietary regimen. Genetic counselling is strongly recommended for all individuals receiving a molecular diagnosis of myoadenylate deaminase deficiency.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Safety Advisory
Do not discontinue prescribed medication or supplements without consulting your treating physician.
- Exclusion Criteria: Active rhabdomyolysis episode (CK >10× ULN within 48 hours); recent blood transfusion (<2 weeks).
- Emergency Red Flags (Call 998 / 999 immediately): Severe muscle pain with cola‑coloured urine, unexplained swelling/tenderness in limbs, or sudden inability to urinate.
- Paediatric patients (<18 years) require mandatory genetic counselling and parental consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What exactly does the AMPD1 genetic test reveal?
The analysis identifies clinically relevant sequence variants in the AMPD1 gene that can cause myoadenylate deaminase deficiency, a disorder linked to exercise‑induced muscle pain and rhabdomyolysis.
2. How long does it take to receive my results after sample collection?
The complete analytical pipeline—from DNA extraction to bioinformatic interpretation and clinical reporting—is finalised within 3 to 4 weeks.
3. Is home sample collection available across all emirates?
Yes, our DHA‑approved mobile phlebotomy team serves Abu Dhabi, Dubai, Sharjah, Ajman, Umm Al‑Quwain, Ras Al‑Khaimah, and Fujairah daily from 8 AM to 11 PM.
4. What are the insurance and billing options for this test?
We provide direct billing verification with major insurers. Send your policy details via WhatsApp to +971 54 548 8731 and our billing team will confirm coverage within 30 minutes.
5. Will my results be discussed with me by a qualified physician?
Yes, every report includes a complimentary telephonic consultation with a DHA‑licensed specialist who will explain the findings, answer your questions, and outline management recommendations.
UAE Regulatory & Data Privacy Adherence
Privacy & Compliance Framework
- Data Protection: All health data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Patient Consent: Specimen collection and genetic analysis are conducted under the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent and patient safety.
- Accreditation: Laboratory certified ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Diagnostic sensitivity validated against international reference standards.
Clinical & Logistical Metadata
| Test Name | AMPD1 Gene Myopathy (Myoadenylate Deaminase Deficiency) Genetic Test – NGS |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Dried Blood Spot (DBS) |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeq) |
| ICD-10-CM Code | E79.2, Z15.89, Z13.79 |
| LOINC Code | 51956‑7 |
| DHA Facility License & Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians